Compare · PRVA vs TOI
PRVA vs TOI
Side-by-side comparison of Privia Health Group Inc. (PRVA) and The Oncology Institute Inc. (TOI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRVA and TOI operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- PRVA is the larger of the two at $2.89B, about 5.6x TOI ($512.9M).
- Over the past year, PRVA is down 11.8% and TOI is up 34.0% - TOI leads by 45.8 points.
- PRVA has hit the wire 2 times in the past 4 weeks while TOI has been quiet.
- PRVA has more recent analyst coverage (25 ratings vs 8 for TOI).
- Company
- Privia Health Group Inc.
- The Oncology Institute Inc.
- Price
- $22.53-0.40%
- $5.12+5.13%
- Market cap
- $2.89B
- $512.9M
- 1M return
- +12.23%
- -3.12%
- 1Y return
- -11.75%
- +34.03%
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 2
- 0
- Recent ratings
- 25
- 8
Privia Health Group Inc.
Privia Health Group, Inc. operates as a physician practice management and population health technology company in the United States. The company comprises regional medical groups, accountable care organizations, and specialty verticals. It offers technology and population health tools to enhance independent providers' workflows; management service organization that enables providers to reduce administrative work focus on their patients; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; physician-led accountable care organization, which engages patients, reduces inappropriate utilization, and enhances coordination and patient quality metrics to drive value-based care and transform the healthcare delivery system; and network for purchasers and payers. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. operates as a subsidiary of Brighton Health Group Holdings, LLC.
The Oncology Institute Inc.
The Oncology Institute, Inc. provides cancer awareness, prevention, diagnosis, treatment, and education service. The company offers chemotherapy education, comprehensive lab testing, pain management, financial counseling, end of life counseling, dietary counseling, in-house infusion center, in-house support groups, in-house pharmacy, nutraceuticals, clinical trials, and educational seminars. It also operates the hope, health, and healing center to offer patients alternative and holistic treatments in addition to chemotherapy. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Latest PRVA
- Privia Health to Report Third Quarter 2026 Results on Thursday, November 5
- Amendment: SEC Form SCHEDULE 13G/A filed by Privia Health Group Inc.
- Director Ernest Opella Finley was granted 6,350 shares (SEC Form 4)
- SEC Form 3 filed by new insider Ernest Opella Finley
- Privia Health Group Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors
- SEC Form 10-Q filed by Privia Health Group Inc.
- Privia Health Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results
- EVP & Chief Financial Officer Mountcastle David sold $588,679 worth of shares (21,275 units at $27.67) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 164,853 units (SEC Form 4)
Latest TOI
- The Oncology Institute Inc. filed SEC Form 8-K: Leadership Update
- Director Hively Brad sold $1,946,310 worth of shares (298,853 units at $6.51), decreasing direct ownership by 42% to 411,976 units (SEC Form 4)
- The Oncology Institute Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Large owner Chernett Jorey bought $78,480 worth of shares (12,000 units at $6.54), increasing direct ownership by 0.11% to 10,660,858 units (SEC Form 4)
- SEC Form 10-Q filed by The Oncology Institute Inc.
- The Oncology Institute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- The Oncology Institute Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- The Oncology Institute Rebrands as Starling Oncology
- Director Kaushal Mohit was granted 33,133 shares, increasing direct ownership by 19% to 205,716 units (SEC Form 4)
- Director Mcgeorge Anne was granted 41,165 shares, increasing direct ownership by 14% to 332,535 units (SEC Form 4)